Results 51 to 60 of about 7,522 (217)

Androgen Receptor Expression in Urothelial Bladder Cancer—A Systematic Review and Meta‐Analysis

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background Bladder cancer is a globally prevalent malignancy with a marked male predominance. Over the past decade, the androgen receptor has been investigated as a potential contributor to bladder cancer pathophysiology. Androgen receptor expression is most commonly assessed via immunohistochemistry, but its association with pathological ...
Alex Buckby, Mandana Gholami, Matthew Hong, Michael O'Callaghan   +3 more
wiley   +1 more source

Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT

Health Technology Assessment
Background Transurethral resection of bladder tumour has been the mainstay of bladder cancer staging for > 60 years. Staging inaccuracies are commonplace, leading to delayed treatment of muscle-invasive bladder cancer.
Nicholas James, Sarah Pirrie, Wenyu Liu, James Catto, Kieran Jefferson, Prashant Patel, Ana Hughes, Ann Pope, Veronica Nanton, Harriet P Mintz, Allen Knight, Jean Gallagher, Richard T Bryan   +12 more
doaj   +1 more source

A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy

BJU International, Volume 135, Issue 4, Page 648-656, April 2025.
Objective To further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non‐coding RNA (lncRNA)‐based genomic profiling has suggested utility in identifying a distinct tumour subgroup corresponding to a favourable prognosis in patients with bladder cancer.
Joep J. de Jong, James A. Proudfoot, Siamak Daneshmand, Robert S. Svatek, Vikram Narayan, Ewan A. Gibb, Elai Davicioni, Shreyas Joshi, Aaron Dahmen, Roger Li, Brant A. Inman, Paras Shah, Iftach Chaplin, Jonathan Wright, Yair Lotan   +14 more
wiley   +1 more source

The Simbla TURBT Simulator in Urological Residency Training: From Needs Analysis to Validation [PDF]

, 2016
Objective: To investigate the value of the physical Simbla Transurethral Resection of a Bladder Tumor (TURBT) simulator as an educational tool within urological residency training, by means of a training needs analysis (TNA) and assessment of its ...
Tjiam, Irene M., Koldewijn, Evert L., Wagner, Cordula, de Vries, Anna H., van Merrienboer, Jeroen J. G., Schout, Barbara M. A., van Genugten, Hilde G. J., Hendrikx, Ad J. M., Muijtjens, Arno M. M.   +8 more
core   +2 more sources

Role of restage transurethral resection of bladder tumor in high-risk non-muscle invasive bladder cancer

National Journal of Physiology, Pharmacy and Pharmacology
Background: Patients with non-muscle invasive bladder cancer (NMIBC) often have transurethral resection of the bladder tumor (TURBT). Inadequate TURBT, floating tumor cell implantation theory, and non-visualized microtumors are major factors for the ...
Dhaval Desai, Ankit Gupta, Umesh Sharma, Hemant Goel, Varun Katiyar, Ketan Mehra   +5 more
doaj   +1 more source

Development and validation of the TOCO-TURBT tool: a summative assessment tool that measures surgical competency in transurethral resection of bladder tumour [PDF]

, 2018
BackgroundThe current shift towards competency-based residency training has increased the need for objective assessment of skills. In this study, we developed and validated an assessment tool that measures technical and non-technical competency in ...
Tjiam, Irene M., Hendrikx, Ad. J. M., Cordula Wagner, Koldewijn, Evert L., van der Vleuten, Cees P. M.; id_orcid, Jeroen J. G. van Merriënboer, Wagner, Cordula, de Vries, Anna H., Barbara M. A. Schout, Ad. J. M. Hendrikx, Hilde G. J. van Genugten, Irene M. Tjiam, van der Vleuten, Cees P. M., Evert L. Koldewijn, Arno. M. M. Muijtjens, Muijtjens, Arno. M. M., van Merrienboer, Jeroen J. G., Anna H. de Vries, Schout, Barbara M. A., van Genugten, Hilde G. J., Cees P. M. van der Vleuten   +20 more
core   +2 more sources

Various Histomorphologic Patterns of Urothelial Carcinoma in TURBT Specimen

esculapio, 2021
Objective: To evaluate the various morphologic patterns of urothelial carcinoma in transurethral resection specimen of urinary bladder. Method: One hundred ninty three biopsies of transurethral resection of bladder from different age groups without exception of sex and race were included in this study from year 2013-2019 in Services Hospital Lahore ...
Hira Kareem, Amna Jahan, Iram Nadeem, Samra Sameen, Rajia Liaqat, Tahira Liaquat   +5 more
openaire   +1 more source

Hybrid grading systems improve progression risk stratification in non‐invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression

Histopathology, EarlyView.
Hybrid grading systems significantly improve progression‐risk stratification in non‐invasive papillary urothelial carcinoma compared with the WHO 2004/2016 binary classification, with most benefit achieved by a Hybrid 3‐Tier framework. These findings support the existence of a histomorphological continuum of progression risk within the conventional ...
Jane K Nguyen, Marcello P Toscano, Jianbo Li, Sean R Williamson, Christopher G Przybycin, Chia‐Sui Kao, Jonathan L Myles, Kristýna Pivovarčíková, Marián Švajdler, Marek Brousil, Mohamed Eltemamy, Laura Bukavina, Venkatesh Krishnamurthi, Christopher Weight, Rebecca A Campbell, Nima Almassi, Reza Alaghehbandan   +16 more
wiley   +1 more source

Kaplan–Meier curves of the intravesical recurrence-free survival rates for TURBT using with and without surgical checklist groups.

, 2022
Kaplan–Meier curves of the intravesical recurrence-free survival rates for TURBT using with and without surgical checklist groups.
Ryuji Matsumoto (1992658), Nobuo Shinohara (667646), Hiroshi Kikuchi (2222737), Takahiro Osawa (174382), Takashige Abe (7302572), Satoru Maruyama (14020136), Sachiyo Murai (12245219)   +6 more
core   +1 more source

Pseudoprogression During Enfortumab Vedotin Plus Pembrolizumab Therapy in Muscle‐Invasive Bladder Cancer Achieving Pathological Complete Response: A Case Report

IJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Enfortumab vedotin plus pembrolizumab has emerged as a standard first‐line therapy for advanced urothelial carcinoma (UC). However, pseudoprogression during this combination remains poorly characterized. Case Presentation A 71‐year‐old man with muscle‐invasive bladder cancer and lymph node metastasis received enfortumab vedotin ...
Yosuke Nakanishi, Yohei Kawashima, Masanao Shinohara, Kazuhisa Hagiwara, Kohei Inui, Kazue Ogawa, Daiji Fujimori, Shingo Moriyama, Hanako Oba, Sato Satoshi   +9 more
wiley   +1 more source